Detection of neuroendocrine tumors using promoter-specific secreted Gaussia luciferase.

Accurate detection of neuroendocrine (NE) tumors is critically important for better prognosis and treatment outcomes in patients. To demonstrate the efficacy of using an adenoviral vector for the detection of NE tumors, we have constructed a pair of adenoviral vectors which, in combination, can conditionally replicate and release Gaussia luciferase into the circulation after infecting the NE tumors. The expression of these two vectors is regulated upstream by an INSM1-promoter (insulinoma-associated-1) that is specifically active in NE tumors and developing NE tissues, but silenced in normal adult tissues. In order to retain the tumor-specificity of the INSM1 promoter, we have modified the promoter using the core insulator sequence from the chicken β-globin HS4 insulator and the neuronal restrictive silencing element (NRSE). This modified INSM1-promoter can retain NE tumor specificity in an adenoviral construct while driving a mutated adenovirus E1A gene (∆24E1A), the Metridia, or Gaussia luciferase gene. The in vitro cell line and mouse xenograft human tumor studies revealed the NE specificity of the INSM1-promoter in NE lung cancer, neuroblastoma, medulloblastoma, retinoblastoma, and insulinoma. When we combined the INSM1-promoter driven Gaussia luciferase with ∆24E1A, the co-infected NE tumor secreted higher levels of Gaussia luciferase as compared to the INSM1p-Gaussia virus alone. In a mouse subcutaneous xenograft tumor model, the combination viruses secreted detectable level of Gaussia luciferase after infecting an INSM1-positive NE lung tumor for ≥12 days. Therefore, the INSM1-promoter specific conditional replicating adenovirus represents a sensitive diagnostic tool to aid clinicians in the detection of NE tumors.

[1]  X. Forns,et al.  A Gaussia Luciferase Cell-Based System to Assess the Infection of Cell Culture- and Serum-Derived Hepatitis C Virus , 2012, PloS one.

[2]  M. Breslin,et al.  Modifications to the INSM1 promoter to preserve specificity and activity for use in adenoviral gene therapy of neuroendocrine carcinomas , 2012, Cancer Gene Therapy.

[3]  B. Wiedenmann,et al.  Neuroendocrine tumors of midgut and hindgut origin: Tumor‐node‐metastasis classification determines clinical outcome , 2011, Cancer.

[4]  M. Breslin,et al.  Structure, expression, and biological function of INSM1 transcription factor in neuroendocrine differentiation , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[5]  S. Pääbo,et al.  Insulinoma-Associated 1 Has a Panneurogenic Role and Promotes the Generation and Expansion of Basal Progenitors in the Developing Mouse Neocortex , 2008, Neuron.

[6]  C. Birchmeier,et al.  Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage , 2008, Development.

[7]  G. Stamatoyannopoulos,et al.  Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. , 2007, Human gene therapy.

[8]  C. Birchmeier,et al.  The zinc-finger factor Insm1 (IA-1) is essential for the development of pancreatic beta cells and intestinal endocrine cells. , 2006, Genes & development.

[9]  R. F. Luco,et al.  IA1 is NGN3‐dependent and essential for differentiation of the endocrine pancreas , 2006, The EMBO journal.

[10]  D. Frappaz,et al.  Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M. Lan,et al.  The zinc-finger transcription factor INSM1 is expressed during embryo development and interacts with the Cbl-associated protein. , 2002, Genomics.

[12]  M. Breslin,et al.  Neuroendocrine differentiation factor, IA-1, is a transcriptional repressor and contains a specific DNA-binding domain: identification of consensus IA-1 binding sequence. , 2002, Nucleic acids research.

[13]  A. Argiris,et al.  Staging and clinical prognostic factors for small-cell lung cancer. , 2001, Cancer journal.

[14]  L. Rorke,et al.  Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Lan,et al.  IA-1, a new marker for neuroendocrine differentiation in human lung cancer cell lines. , 1993, Cancer research.

[16]  Johnson Be,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[17]  M. de Silva,et al.  A novel human insulinoma-associated cDNA, IA-1, encodes a protein with "zinc-finger" DNA-binding motifs. , 1992, The Journal of biological chemistry.

[18]  Stephen H. Friend,et al.  Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product , 1988, Nature.

[19]  Mountain Cf.  Clinical biology of small cell carcinoma: relationship to surgical therapy. , 1978 .

[20]  B. Wiedenmann,et al.  Neuroendocrine neoplasms of the gut and pancreas: new insights , 2012, Nature Reviews Endocrinology.

[21]  C. Miao,et al.  Secreted Luciferase for In Vivo Evaluation of Systemic Protein Delivery in Mice , 2012, Molecular Biotechnology.

[22]  B. Johnson,et al.  The biology of lung cancer. , 1993, Seminars in oncology.

[23]  J Pritchard,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Green,et al.  Surgicopathologic staging of neuroblastoma: prognostic significance of regional lymph node metastases. , 1983, The Journal of pediatrics.